文献速递关节外科

不同体重指数水平初次全髋关节置换患者的90天费用、再手术和再入院情况

Ninety-Day Costs, Reoperations, and Readmissions for Primary Total Hip Arthroplasty Patients of Varying Body Mass Index Levels.
PubMed 文献 · J Arthroplasty · 2018-11-24

本研究回顾性比较了初次全髋关节置换术中非肥胖(BMI 18.5-24.9)与超重、肥胖、重度肥胖、病态肥胖及超级肥胖患者90天费用和结局。病态肥胖和超级肥胖组90天费用显著高于非肥胖组,仅超级肥胖组90天再手术率和再入院率高于非肥胖组。超级肥胖组3年再手术率和感染性翻修率也更高,但各组的健康调查简表、Harris髋关节评分和西安大略与麦克马斯特大学骨关节炎指数的改善程度相当。

要点

  • 病态肥胖(BMI 40-44.9)和超级肥胖(BMI≥45)患者90天费用显著高于非肥胖患者。
  • 仅超级肥胖患者90天再手术率和再入院率显著高于非肥胖患者。
  • 超级肥胖患者3年再手术率和感染性翻修率显著高于非肥胖患者,但生活质量改善程度相当。

核心结论

  • 超级肥胖患者相比非肥胖患者具有更高的风险和费用,但生活质量改善程度相当。

研究设计与样本

  • 回顾性审查2006年至2013年机构数据库中初次全髋关节置换患者,超级肥胖组33例,其他5组按2:1比例随机选取共363例。

主要发现

  • 病态肥胖组90天费用为13134±7250美元(均值±标准差,P<.01),超级肥胖组为15604±6783美元(P<.01),均显著高于非肥胖组的10315±1848美元。
  • 仅超级肥胖组90天再手术率(18.2% vs 0%,P<.01)和再入院率(21.2% vs 4.5%,P=.02)高于非肥胖组。
  • 超级肥胖组3年再手术率(21.2% vs 3.0%,P=.01)和感染性翻修率(18.2% vs 1.5%,P=.01)高于非肥胖组。
  • 健康调查简表、Harris髋关节评分和西安大略与麦克马斯特大学骨关节炎指数的改善在所有队列中相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study is to compare 90-day costs and outcomes for primary total hip arthroplasty patients between a nonobese (body mass index, 18.5-24.9) vs overweight (25-29.9), obese (30-34.9), severely obese (35-39.9), morbidly obese (40-44.9), and super obese (45+) cohorts. METHODS: We conducted a retrospective review of an institutional database of primary total hip arthroplasty patients from 2006 to 2013. Thirty-three super-obese patients were identified, and the other 5 cohorts were randomly selected in a 2:1 ratio (n = 363). Demographics, 90-day outcomes (costs, reoperations, and readmissions), and outcomes after 3 years (revisions and change scores for Short-Form Health Survey, Harris Hip Score, and Western Ontario and McMaster Universities Arthritis Index) were collected. Costs were determined using unit costs from our institutional administrative data for all in-hospital resource utilization. Comparisons between the nonobese and other groups were made with Kruskal-Wallis tests for non-normal data and chi-square and Fisher exact test for categorical data. RESULTS: The 90-day costs in the morbidly obese ($13,134 ± $7250 mean ± standard deviation, P < .01) and super-obese ($15,604 ± 6783, P < .01) cohorts were significantly greater than the nonobese cohorts ($10,315 ± 1848). Only the super-obese cohort had greater 90-day reoperation and readmission rates than the nonobese cohort (18.2% vs 0%, P < .01 and 21.2% vs 4.5%, P = .02, respectively). Reoperations and septic revisions after 3 years were greater in the super-obese cohort compared to the nonobese cohort 21.2% versus 3.0% (P = .01) and 18.2% versus 1.5% (P = .01), respectively. Improvements in Short-Form Health Survey, Harris Hip Score, and Western Ontario and McMaster Universities Arthritis Index were comparable in all cohorts. CONCLUSION: Super-obese patients have greater risks and costs compared to nonobese patients, but also have comparable quality of life improvements.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Ponnusamy KE, Marsh JD, Somerville LE, et al. Ninety-Day Costs, Reoperations, and Readmissions for Primary Total Hip Arthroplasty Patients of Varying Body Mass Index Levels. J Arthroplasty. 2018. PMID: 30559012. doi:10.1016/j.arth.2018.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。